Gilead Sciences Portfolio holdings
Gilead Sciences is an American biopharmaceutical company that researches and develops antiviral drugs for HIV/AIDS, hepatitis B and C, influenza and COVID-19. Michael Riordan, a doctor who was then an associate at the venture firm Menlo Ventures, founded it in 1987 as Oligogen, a name pointing to oligonucleotides, small strands of DNA. Riordan used Oligogen only while clearing a trademark issue with a California nonprofit, and he took the Gilead name from the Balm of Gilead, which he first met in a Lanford Wilson play. Gilead discovered the flu drug Tamiflu and licensed it to Roche, and its 2011 purchase of Pharmasset brought it sofosbuvir, approved in 2013 as the hepatitis C treatment Sovaldi. In 2017 Gilead said it would acquire Kite Pharma as its entry into cell therapy, a deal that had produced two lymphoma treatments, Yescarta and Tecartus, by 2022.
Top Buys
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kalaris Therapeutics
KLRS
|
+$1.83M |
| 2 |
ImageneBio Inc
IMA
|
+$992K |
| 3 |
BRNS
Barinthus Biotherapeutics
BRNS
|
+$236K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.13B
| $468M | 36.53% |
16,707,477
| – | – |
2024 Q4
2 quarters
|
|
2
DELISTED
Arcellx
ACLX
| $443M | 34.57% |
6,720,803
| – | – |
2024 Q4
2 quarters
|
|
3
Arcus Biosciences
RCUS
$2.32B
| $256M | 19.98% |
31,424,760
| – | – |
2024 Q4
2 quarters
|
|
4
Assembly Biosciences
ASMB
$410M
| $40M | 3.13% |
2,209,471
| – | – |
2024 Q4
2 quarters
|
|
5
Tango Therapeutics
TNGX
$3.83B
| $24.9M | 1.94% |
4,854,443
| – | – |
2024 Q4
2 quarters
|
|
6
DELISTED
Merus
MRUS
| $23.8M | 1.86% |
452,527
| – | – |
2024 Q4
2 quarters
|
|
7
Kyverna Therapeutics
KYTX
$351M
| $12.7M | 0.99% |
4,126,119
| – | – |
2024 Q4
2 quarters
|
|
8
Xilio Therapeutics
XLO
$52.8M
| $6.19M | 0.48% |
650,389
| – | – |
2024 Q4
2 quarters
|
|
9
DELISTED
HOOKIPA Pharma
HOOK
| $2.35M | 0.18% |
1,875,945
| – | – |
2024 Q4
2 quarters
|
|
10
Cypherpunk Technologies Inc
CYPH
$321M
| $1.58M | 0.12% |
5,319,148
| – | – |
2024 Q4
2 quarters
|
|
11
Allogene Therapeutics
ALLO
$408M
| $1.31M | 0.1% |
1,156,689
| – | – |
2024 Q4
2 quarters
|
|
|
12
Kalaris Therapeutics
KLRS
$48.3M
| $848K | 0.07% |
317,789
-405,484
| -56% | -$1.83M |
2024 Q4
2 quarters
|
|
|
13
ImageneBio Inc
IMA
$46.5M
| $467K | 0.04% |
29,045
-67,550
| -70% | -$992K |
2024 Q4
2 quarters
|
|
|
BRNS
14
DELISTED
Barinthus Biotherapeutics
BRNS
| $92.5K | 0.01% |
99,478
-270,377
| -73% | -$236K |
2024 Q4
2 quarters
|
|
Similar funds
Gilead Sciences's Q2 2025 Portfolio in Review
As of Q2 2025, Gilead Sciences held 14 positions worth $1.28B, up 8.4% from $1.18B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q2 2025: portfolio turnover was 0%. Gilead Sciences opened no new positions and made no exits, leaving the 14-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
- Gilead Sciences's biggest Q2 2025 reduction was Kalaris Therapeutics, cutting an estimated $1.83M.
- Gilead Sciences's ten largest holdings make up 100% of its $1.28B portfolio in Q2 2025.
- Gilead Sciences opened 0 new positions and closed 0 in Q2 2025.
- Gilead Sciences's portfolio value rose 8.4% quarter-over-quarter to $1.28B.
Based on Gilead Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.